KemPharm, Inc. Common Stock, also called KemPharm, is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. Read More It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.